| CYTK |
Cytokinetics, Incorporated |
92%
|
Reciprocal relationship from CYTK graph: We have entered into certain revenue participation right purchase agreements for omecamtiv mecarbil, aficamten, and CK-586 with affiliates of Royalty Pharma, … |
| DNLI |
Denali Therapeutics Inc. |
90%
|
Reciprocal relationship from DNLI graph: Reciprocal relationship from RPRX graph: Reciprocal relationship from DNLI graph: The information contained in Item 1.01 of the Form 8-K filed by Denali Thera… |
| SNDX |
Syndax Pharmaceuticals, Inc. |
90%
|
Reciprocal relationship from SNDX graph: the Purchase and Sale Agreement provides that if certain events of default occur, including certain bankruptcy events or certain termination events with respe… |
| VERTEX |
VERTEX |
90%
|
Royalty payor that accounted for 36% of our total income and other revenues in 2024 and 2023 |
| ARWR |
Arrowhead Pharmaceuticals, Inc. |
85%
|
Reciprocal relationship from ARWR graph: Reciprocal relationship from RPRX graph: Reciprocal relationship from ARWR graph: Reciprocal relationship from RPRX graph: Reciprocal relationship from ARWR g… |
| ROCHE |
ROCHE |
80%
|
Royalty payor that accounted for 10% of our total income and other revenues in 2024 |
| JNJ |
Johnson & Johnson |
72%
|
. As a result of our significant scale and highly flexible business model, we believe that we are uniquely positioned to capitalize on multiple compounding growth drivers: an accelerating understandi… |
| JNJ |
Johnson & Johnson |
72%
|
Reciprocal relationship from JNJ graph: Reciprocal relationship from RPRX graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from RPRX graph: . As a result of our significant scal… |
| NUVL |
Nuvalent, Inc. |
72%
|
Reciprocal relationship from NUVL graph: Reciprocal relationship from RPRX graph: Reciprocal relationship from NUVL graph: d other current assets of $16.9 million. During the year ended December 31, … |
| SNYNF |
Sanofi |
72%
|
1, 2024 and 2023 based on a discounted cash flow calculation using estimated risk-adjusted discount rates, which are Level 3 inputs. Our estimate of the risk adjusted discount rates could reasonably … |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from RPRX graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from RPRX graph: 1, 2024 and 2023 based on a disco… |
| TBPH |
Theravance Biopharma, Inc. |
72%
|
. As a result of our significant scale and highly flexible business model, we believe that we are uniquely positioned to capitalize on multiple compounding growth drivers: an accelerating understandi… |
| TBPH |
Theravance Biopharma, Inc. |
72%
|
Reciprocal relationship from TBPH graph: Reciprocal relationship from RPRX graph: Reciprocal relationship from TBPH graph: Reciprocal relationship from RPRX graph: . As a result of our significant sc… |
| APIJECT-HOLDINGS-INC |
APIJECT-HOLDINGS-INC |
62%
|
ing derivative instruments such as treasury rate lock contracts. Our policy is to use derivatives strategically to hedge existing and future interest rate exposure and to minimize volatility in cash … |
| FOLLOWING-PFIZER-INC |
FOLLOWING-PFIZER-INC |
62%
|
ing derivative instruments such as treasury rate lock contracts. Our policy is to use derivatives strategically to hedge existing and future interest rate exposure and to minimize volatility in cash … |
